Biogen Inc. (BIIB)

Biotech medicines maker, 56% in the U.S. Read October 19, 2026 from the annual report for the period ending December 31, 2025, filed February 6, 2026. Ranked 63 of the 104 Healthcare companies read so far, by the share within reach now.

A biotechnology company whose filing states 7,500 employees with 4,200 in the U.S. and nothing by kind of work, so the whole workforce is read at pharmaceutical manufacturing.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 19% now, 34% at the end of 2027, 41% at the end of 2028, 44% at the end of 2030. By the patterns, the work is about 44% desk work, 14% people work and 42% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 57% of the working time stays with people (conversation, in-person and hands-on work), 36% becomes checking a model's work and 4% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

7,500 employees as of December 31, 2025 (stated). Stated by count: approximately 4,200 of 7,500 employees in the U.S. and 3,300 in foreign countries.

The filing: “As of December 31, 2025, we had approximately 7,500 employees worldwide. Approximately 4,200 employees were employed in the U.S. and approximately 3,300 employees were employed in foreign countries.”

The workforce as industry patterns

What the filing says about the workforce: Approximately 7,500 employees worldwide as of December 31, 2025 (7,605 a year earlier): about 4,200 in the U.S. and 3,300 abroad; the filing records that its Fit for Growth program included net headcount reductions of approximately 1,400 employees by the end of 2025; 50% of director-level and above positions held by women.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• Johnson & Johnson (JNJ, 140,800 employees)19% now, 39% by 2028
• Thermo Fisher Scientific Inc. (TMO, 125,000 employees)20% now, 49% by 2028
• Merck & Co., Inc. (MRK, 75,000 employees)19% now, 41% by 2028
• Pfizer Inc. (PFE, 75,000 employees)19% now, 41% by 2028
• AbbVie Inc. (ABBV, 57,000 employees)19% now, 41% by 2028
• Eli Lilly and Company (LLY, 50,000 employees)19% now, 41% by 2028
• Bristol-Myers Squibb Company (BMY, 32,500 employees)19% now, 41% by 2028
• Amgen Inc. (AMGN, 31,500 employees)19% now, 41% by 2028

What the filing says about AI

10 sentences in the filing name AI. The filing names AI in its glossary and among the cyber threat landscape, where adversarial AI techniques and machine learning accompany more extortion attacks; it names AI in 10 sentences.

• “We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, factors relating to: our substantial dependence on the anticipated amount, timing and accounting of revenue from our products, including from t...”
• “AI Artificial Intelligence Alcyone Alcyone Therapeutics, Inc.”
• “Recent developments in the threat landscape include use of adversarial AI techniques and machine learning, as well as an increased number of cyber extortion attacks, with higher financial ransom demand amounts and increasing sophistication and variety of ransomware techniques and methodology.”
• “The increasing use of AI-based software presents new risks and challenges and could adversely affect our business and reputation.”
• “As with many developing technologies, AI-based software presents risks and challenges.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20211median 0
• Fiscal 20220median 0
• Fiscal 20235median 1
• Fiscal 202410median 4
• Fiscal 202510median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• No count by kind of work: research, manufacturing and commercial staff are read at one pattern by description (c).

Source: the company's annual report on EDGAR, accession 0000875045-26-000013, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.